33.09
price down icon1.22%   -0.41
 
loading
Schlusskurs vom Vortag:
$33.50
Offen:
$33.66
24-Stunden-Volumen:
1.38M
Relative Volume:
0.49
Marktkapitalisierung:
$4.54B
Einnahmen:
$264.79M
Nettoeinkommen (Verlust:
$-14.36M
KGV:
-300.82
EPS:
-0.11
Netto-Cashflow:
$-28.11M
1W Leistung:
+4.38%
1M Leistung:
+18.18%
6M Leistung:
+65.53%
1J Leistung:
+130.27%
1-Tages-Spanne:
Value
$32.70
$34.20
1-Wochen-Bereich:
Value
$30.59
$34.20
52-Wochen-Spanne:
Value
$12.84
$36.84

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name
Firmenname
Tg Therapeutics Inc
Name
Telefon
(212) 554-4484
Name
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Name
Mitarbeiter
0
Name
Twitter
@TGTherapeutics
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
TGTX's Discussions on Twitter

Vergleichen Sie TGTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TGTX
Tg Therapeutics Inc
33.09 4.54B 264.79M -14.36M -28.11M -0.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.32 120.86B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
710.00 77.62B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
646.64 39.62B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.19 35.50B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.61 28.20B 3.30B -501.07M 1.03B -2.1146

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-29 Eingeleitet TD Cowen Buy
2023-08-02 Hochstufung Goldman Sell → Neutral
2023-06-26 Fortgesetzt Jefferies Buy
2022-05-20 Eingeleitet BofA Securities Underperform
2022-02-23 Bestätigt B. Riley Securities Buy
2021-11-15 Herabstufung Goldman Neutral → Sell
2021-04-20 Eingeleitet Goldman Neutral
2021-04-19 Bestätigt H.C. Wainwright Buy
2020-09-01 Eingeleitet JP Morgan Overweight
2020-08-11 Bestätigt H.C. Wainwright Buy
2020-06-05 Eingeleitet Evercore ISI Outperform
2020-01-17 Bestätigt H.C. Wainwright Buy
2019-11-27 Fortgesetzt B. Riley FBR Buy
2019-02-06 Fortgesetzt Jefferies Buy
2018-09-25 Herabstufung Raymond James Strong Buy → Outperform
2018-03-09 Bestätigt B. Riley FBR, Inc. Buy
2017-12-01 Fortgesetzt B. Riley FBR, Inc. Buy
2017-11-14 Fortgesetzt H.C. Wainwright Buy
2017-04-25 Eingeleitet Jefferies Buy
2017-03-06 Bestätigt FBR & Co. Outperform
2016-10-06 Fortgesetzt Brean Capital Buy
2016-05-27 Eingeleitet SunTrust Buy
2015-12-01 Eingeleitet FBR Capital Outperform
2015-09-09 Eingeleitet Raymond James Strong Buy
2015-08-12 Fortgesetzt H.C. Wainwright Buy
2015-06-19 Bestätigt Brean Capital Buy
2014-12-11 Bestätigt ROTH Capital Buy
2014-12-10 Bestätigt ROTH Capital Buy
Alle ansehen

Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten

pulisher
04:07 AM

Stratos Wealth Advisors LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

04:07 AM
pulisher
Feb 08, 2025

SG Americas Securities LLC Has $233,000 Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$199m market cap gain - Simply Wall St

Feb 08, 2025
pulisher
Feb 08, 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Feb 08, 2025
pulisher
Feb 06, 2025

TGTX March 28th Options Begin Trading - Nasdaq

Feb 06, 2025
pulisher
Feb 06, 2025

Symphony Financial Ltd. Co. Acquires New Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 06, 2025
pulisher
Feb 04, 2025

TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Sell" at StockNews.com - MarketBeat

Feb 04, 2025
pulisher
Feb 02, 2025

Precision Wealth Strategies LLC Buys Shares of 17,608 TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 02, 2025
pulisher
Jan 30, 2025

Nisa Investment Advisors LLC Buys 2,803 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Jan 30, 2025
pulisher
Jan 28, 2025

Trading (TGTX) With Integrated Risk Controls - Stock Traders Daily

Jan 28, 2025
pulisher
Jan 28, 2025

All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy - MSN

Jan 28, 2025
pulisher
Jan 25, 2025

TG Therapeutics (NASDAQ:TGTX) Stock Price Up 6.8%Here's What Happened - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

Why TGTX Stock Is Rallying Today - MSN

Jan 25, 2025
pulisher
Jan 23, 2025

TG Therapeutics: Entering 2025 With Increased Investor Expectations (NASDAQ:TGTX) - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Weighs in on TG Therapeutics FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Decreases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Jan 22, 2025
pulisher
Jan 21, 2025

TG Therapeutics: 2025 Revenues Will Smash Expectations (NASDAQ:TGTX) - Seeking Alpha

Jan 21, 2025
pulisher
Jan 20, 2025

12 Hot Stocks to Buy According to Analysts - Insider Monkey

Jan 20, 2025
pulisher
Jan 20, 2025

Here’s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX) - Insider Monkey

Jan 20, 2025
pulisher
Jan 18, 2025

TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last? - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

(TGTX) Trading Signals - Stock Traders Daily

Jan 18, 2025
pulisher
Jan 18, 2025

Brookstone Capital Management Acquires 624 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

FY2024 EPS Forecast for TG Therapeutics Increased by Analyst - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Is TG Therapeutics Inc. (TGTX) Among Tuesday’s Top Gainers? - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

TG Therapeutics FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

TG Therapeutics Provides Preliminary Fourth Quarter and Full-Year Financial Results in SEC Filing - Defense World

Jan 17, 2025
pulisher
Jan 16, 2025

TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade) (NASDAQ:TGTX) - Seeking Alpha

Jan 16, 2025
pulisher
Jan 16, 2025

TG Therapeutics FY2025 EPS Forecast Raised by HC Wainwright - MarketBeat

Jan 16, 2025
pulisher
Jan 15, 2025

TG Therapeutics' (TGTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

Exploring Three High Growth Tech Stocks In The United States - Yahoo Finance

Jan 15, 2025
pulisher
Jan 15, 2025

Have Insiders Sold TG Therapeutics Shares Recently? - Simply Wall St

Jan 15, 2025
pulisher
Jan 15, 2025

Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts - Benzinga

Jan 15, 2025
pulisher
Jan 15, 2025

TG Therapeutics stock rises on strong Q4 and full-year revenue - Investing.com Australia

Jan 15, 2025
pulisher
Jan 14, 2025

10 Firms Post Impressive Gains on Tuesday - Insider Monkey

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics Reports Strong Revenue and Future Goals - TipRanks

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics Shares Climb 7% as Sales Grow for Multiple Sclerosis Drug - MarketWatch

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics Provides Preliminary Fourth Quarter and - GlobeNewswire

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics (NASDAQ:TGTX) Shares Gap UpHere's Why - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics projects $540 million in 2025 revenue By Investing.com - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 14, 2025

What's Going On With TG Therapeutics Stock Tuesday? - Benzinga

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics says 2024 Briumvi sales topped expectations - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics stock rises on strong Q4 and full-year revenue By Investing.com - Investing.com South Africa

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics stock gains on Briumvi sales (TGTX:NASDAQ) - Seeking Alpha

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics projects $540 million in 2025 revenue - Investing.com

Jan 14, 2025

Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$79.95
price down icon 1.03%
$20.11
price down icon 2.71%
$347.71
price down icon 1.71%
$4.69
price down icon 6.94%
biotechnology ONC
$223.50
price down icon 2.35%
$117.61
price down icon 1.94%
Kapitalisierung:     |  Volumen (24h):